{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:27:09Z","timestamp":1773851229949,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Modelling"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.idm.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:27:43Z","timestamp":1739640463000},"page":"731-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling hepatitis B-related deaths in China to achieve the WHO's impact target"],"prefix":"10.1016","volume":"10","author":[{"given":"Wenjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoru","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihua","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.idm.2025.02.010_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1890\/13-1452.1","article-title":"Model selection for ecologists: The worldviews of AIC and BIC","volume":"95","author":"Aho","year":"2014","journal-title":"Ecology"},{"issue":"8","key":"10.1016\/j.idm.2025.02.010_bib2","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.idm.2025.02.010_bib3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hep.31527","article-title":"ImmTAV, a new immunotherapy targeting the source of HBV infection","volume":"72","author":"Bertoletti","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.idm.2025.02.010_bib4","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"issue":"8","key":"10.1016\/j.idm.2025.02.010_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2471\/BLT.18.219295","article-title":"Treatment of people diagnosed with chronic hepatitis C virus infection","volume":"96","author":"Bulterys","year":"2018","journal-title":"Bulletin of the World Health Organization"},{"issue":"3\u20134","key":"10.1016\/j.idm.2025.02.010_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.mcm.2011.08.017","article-title":"The discrete age-structured SEIT model with application to tuberculosis transmission in China","volume":"55","author":"Cao","year":"2012","journal-title":"Mathematical and Computer Modelling"},{"issue":"11","key":"10.1016\/j.idm.2025.02.010_bib8","first-page":"846","article-title":"Chinese guidelines on the management of liver cirrhosis","volume":"27","year":"2019","journal-title":"Chinese Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.idm.2025.02.010_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jvh.13350","article-title":"Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do","volume":"27","author":"Cuadrado","year":"2020","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1016\/j.idm.2025.02.010_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China","volume":"23","author":"Cui","year":"2017","journal-title":"Emerging Infectious Diseases"},{"issue":"2","key":"10.1016\/j.idm.2025.02.010_bib11","first-page":"81","article-title":"Hepatitis B control in China: Progress, challenges and strategies","volume":"6","author":"Cui","year":"2016","journal-title":"Chin J Viral Dis."},{"issue":"8","key":"10.1016\/j.idm.2025.02.010_bib12","first-page":"725","article-title":"Progress in prevention and control viral hepatitis since the establishing of the People's Republic of China","volume":"29","author":"Cui","year":"2021","journal-title":"Chinese Journal of Hepatology"},{"issue":"2","key":"10.1016\/j.idm.2025.02.010_bib13","first-page":"112","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)","volume":"28","year":"2020","journal-title":"Chinese Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.idm.2025.02.010_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12859-017-2003-3","article-title":"Fast genomic prediction of breeding values using parallel Markov chain Monte Carlo with convergence diagnosis","volume":"19","author":"Guo","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.idm.2025.02.010_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11222-006-9438-0","article-title":"Dram: Efficient adaptive MCMC","volume":"16","author":"Haario","year":"2006","journal-title":"Statistics and Computing"},{"key":"10.1016\/j.idm.2025.02.010_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fninf.2018.00097","article-title":"Robust and fast Markov chain Monte Carlo sampling of diffusion MRI microstructure models","volume":"12","author":"Harms","year":"2018","journal-title":"Front Neuroinform"},{"key":"10.1016\/j.idm.2025.02.010_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7075935","article-title":"Efficacy of nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: A systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Disease Markers"},{"key":"10.1016\/j.idm.2025.02.010_bib18","series-title":"Modeling infectious disease parameters based on serological and social contact data: A modern statistical perspective","author":"Hens","year":"2012"},{"issue":"2","key":"10.1016\/j.idm.2025.02.010_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.idm.2025.02.010_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.12755","article-title":"Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study","volume":"24","author":"Li","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"10","key":"10.1016\/j.idm.2025.02.010_bib21","article-title":"Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies","volume":"5","author":"Li","year":"2023","journal-title":"JHEP Rep"},{"issue":"15","key":"10.1016\/j.idm.2025.02.010_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.idm.2025.02.010_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bulletin of the World Health Organization"},{"issue":"6","key":"10.1016\/j.idm.2025.02.010_bib24","first-page":"605","article-title":"Progress and challenges in achieving the WHO goal on \u201cElimination of Hepatitis B by 2030\u201d in China","volume":"40","author":"Liu","year":"2019","journal-title":"Chinese Journal of Epidemiology"},{"issue":"1","key":"10.1016\/j.idm.2025.02.010_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1186\/s12889-022-13594-y","article-title":"Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.idm.2025.02.010_bib26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.30899","article-title":"Modeling progress toward elimination of hepatitis B in Australia","volume":"71","author":"McCulloch","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.idm.2025.02.010_bib27","first-page":"575","article-title":"Discrete time modelling of disease incidence time series by using Markov chain Monte Carlo methods","volume":"54","author":"Morton","year":"2005","journal-title":"Appl Statist."},{"issue":"3","key":"10.1016\/j.idm.2025.02.010_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<307::AID-SIM15>3.0.CO;2-Z","article-title":"Semi-parametric estimation of age-time specific infection incidence from serial prevalence data","volume":"18","author":"Nagelkerke","year":"1999","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1016\/j.idm.2025.02.010_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/cid\/ciaa134","article-title":"Investment case for a comprehensive package of interventions against hepatitis B in China: Applied modeling to help national strategy planning","volume":"72","author":"Nayagam","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1016\/j.idm.2025.02.010_bib30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: A modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"7","key":"10.1016\/j.idm.2025.02.010_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2893.2009.01117.x","article-title":"Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden","volume":"16","author":"Nguyen","year":"2009","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1016\/j.idm.2025.02.010_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.idm.2025.02.010_bib33","article-title":"Towards the elimination of viral hepatitis in Thailand by the year 2030","volume":"6","author":"Posuwan","year":"2020","journal-title":"J\u00a0Virus Erad"},{"issue":"10","key":"10.1016\/j.idm.2025.02.010_bib34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14712598.2018.1518423","article-title":"Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk","volume":"18","author":"Ren","year":"2018","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1016\/j.idm.2025.02.010_bib35","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","article-title":"Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: An economic evaluation","volume":"10","author":"Su","year":"2022","journal-title":"Lancet Global Health"},{"issue":"Suppl 1","key":"10.1016\/j.idm.2025.02.010_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/liv.13307","article-title":"Novel targets for hepatitis B virus therapy","volume":"37","author":"Testoni","year":"2017","journal-title":"Liver International"},{"issue":"9","key":"10.1016\/j.idm.2025.02.010_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107177","article-title":"Large variations in risk of hepatocellular carcinoma and mortality in treatment na\u00efve hepatitis B patients: Systematic review with meta-analyses","volume":"9","author":"Thiele","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.idm.2025.02.010_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1473-3099(17)30421-8","article-title":"Measles immunity gaps and the progress towards elimination: A multi-country modelling analysis","volume":"17","author":"Trentini","year":"2017","journal-title":"The Lancet Infectious Diseases"},{"issue":"5","key":"10.1016\/j.idm.2025.02.010_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"Rep 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infectious Diseases"},{"issue":"Suppl 4","key":"10.1016\/j.idm.2025.02.010_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"The Oncologist"},{"issue":"2","key":"10.1016\/j.idm.2025.02.010_bib41","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2214-109X(21)00547-7","article-title":"Expanded screening for chronic hepatitis B virus infection in China","volume":"10","author":"Wang","year":"2022","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.idm.2025.02.010_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2471\/BLT.14.139626","article-title":"Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China","volume":"93","author":"Wang","year":"2015","journal-title":"Bulletin of the World Health Organization"},{"issue":"1","key":"10.1016\/j.idm.2025.02.010_bib43","first-page":"1","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2019 version)","volume":"10","author":"Wang","year":"2020","journal-title":"Chin J Viral Dis"},{"issue":"5","key":"10.1016\/j.idm.2025.02.010_bib44","first-page":"487","article-title":"Achievements and prospects for hepatitis B prevention and control in China","volume":"25","author":"Wang","year":"2019","journal-title":"Chin J Vaccine"},{"key":"10.1016\/j.idm.2025.02.010_bib45","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","year":"2015"},{"key":"10.1016\/j.idm.2025.02.010_bib46","series-title":"Global health sector strategy on viral hepatitis 2016-2021","year":"2016"},{"key":"10.1016\/j.idm.2025.02.010_bib47","series-title":"Interim guidance for country validation of viral hepatitis elimination","year":"2021"},{"issue":"4","key":"10.1016\/j.idm.2025.02.010_bib48","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.clinre.2014.12.003","article-title":"Efficacy of antiviral therapy with nucleotide\/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis","volume":"39","author":"Xia","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.idm.2025.02.010_bib49","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/hep.29922","article-title":"Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis","volume":"68","author":"Xie","year":"2018","journal-title":"Hepatology"},{"issue":"39","key":"10.1016\/j.idm.2025.02.010_bib50","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.3748\/wjg.v19.i39.6665","article-title":"Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta- analysis","volume":"19","author":"Ye","year":"2013","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.idm.2025.02.010_bib51","article-title":"Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: An economic evaluation","volume":"35","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"10.1016\/j.idm.2025.02.010_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2017.00073","article-title":"Consensus on pegylated interferon alpha in treatment of chronic hepatitis B","volume":"6","author":"Zhang","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol."},{"issue":"7","key":"10.1016\/j.idm.2025.02.010_bib53","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.cnsns.2013.11.004","article-title":"Dynamic analysis of a hepatitis B model with three-age-classes","volume":"19","author":"Zhang","year":"2014","journal-title":"Communications in Nonlinear Science and Numerical Simulation"},{"issue":"8","key":"10.1016\/j.idm.2025.02.010_bib54","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1137\/090777645","article-title":"An age-structured model for the transmission dynamics of hepatitis B","volume":"70","author":"Zou","year":"2010","journal-title":"SIAM Journal on Applied Mathematics"}],"container-title":["Infectious Disease Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042725000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042725000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:51:34Z","timestamp":1762627894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468042725000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2468042725000119"],"URL":"https:\/\/doi.org\/10.1016\/j.idm.2025.02.010","relation":{},"ISSN":["2468-0427"],"issn-type":[{"value":"2468-0427","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling hepatitis B-related deaths in China to achieve the WHO's impact target","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idm.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd\u00e9","name":"copyright","label":"Copyright"}]}}